TY - JOUR AU - I. Marie, AU - S. Robaday, AU - J.M. Kerleau, AU - F. Jardin, AU - H. Levesque, PY - 2007/05/01 Y2 - 2024/03/29 TI - Typhlitis as a complication of alemtuzumab therapy JF - Haematologica JA - haematol VL - 92 IS - 5 SE - Online Only Articles DO - 10.3324/haematol.11440 UR - https://haematologica.org/article/view/4457 SP - e62-e63 AB - Alemtuzumab is a humanized monoclonal antibody directed against lymphocytes through the CD-52 receptor, an antigen being found on > 95% of peripheral blood lymphocytes and monocytes, and to a smaller extent on granulocytes.1–7 It is an effective immunotherapeutic agent in patients with malignancies such as non-Hodgkin lymphoma, B cell chronic lymphocytic leukemia and T cell prolymphocytic leukemia.1–7 Adverse side effects are increasingly recognized in patients receiving alemtuzumab, mainly including fever, rigors, nausea/vomiting, skin rash; other severe alemtuzumab-related reactions have also been described, such as lymphopenia and neutropenia leading to both opportunistic (e.g. cytomegalovirus) and non-opportunistic infections.7–10 Digestive complications have more rarely been described, i.e.: gastroenteritis and peritonitis.10 We recently observed a case of particular interest as the patient with T cell prolymphocytic leukaemia treated with alemtuzumab, exhibited symptomatic reactivation of CMV infection and developed subsequently typhlitis ER -